External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection
Authors:
- Vito LorussoVLVito Lorusso
- Boukary KabreBKBoukary Kabre
- Geraldine PignotGPGeraldine Pignot
- Nicolas BrangerNBNicolas Branger
- Andrea PacchettiAPAndrea Pacchetti
- Jeanne Thomassin-PianaJTJeanne Thomassin-Piana
- Serge BrunelleSBSerge Brunelle
- Nicola NicolaiNNNicola Nicolai
- Gennaro MusiGMGennaro Musi
- Naji SalemNSNaji Salem
- Emanuele MontanariEMEmanuele Montanari
- Ottavio de CobelliOCOttavio de Cobelli
- 6 March 2022
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (3) , 619-625
Abstract
Purpose Prostate cancer (PCa) imaging has been revolutionized by the introduction of multi-parametric Magnetic Resonance Imaging (mpMRI). Transrectal ultrasound (TRUS) has always been considered a low-performance modality. To overcome this, a computerized artificial neural network analysis (ANNA/C–TRUS) of the TRUS based on an artificial intelligence (AI) analysis has been proposed. Our aim was to evaluate the diagnostic performance of the ANNA/C-TRUS system and its ability to improve conventional TRUS in PCa diagnosis. Methods We retrospectively analyzed data from 64 patients with PCa and scheduled for radical prostatectomy who underwent TRUS followed by ANNA/C-TRUS analysis before the procedure. The results of ANNA/C-TRUS analysis with whole mount sections from final pathology. Results On a per-sectors analysis, sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and accuracy were 62%, 81%, 80%, 64% and 78% respectively. The values for the detection of clinically significant prostate cancer were 69%, 77%, 88%, 50% and 75%. The diagnostic values for high grade tumours were 70%, 74%, 91%, 41% and 74%, respectively. Cancer volume (≤ 0.5 or greater) did not influence the diagnostic performance of the ANNA/C-TRUS system. Conclusions ANNA/C-TRUS represents a promising diagnostic tool and application of AI for PCa diagnosis. It improves the ability of conventional TRUS to diagnose prostate cancer, preserving its simplicity and availability. Since it is an AI system, it does not hold the inter-observer variability nor a learning curve. Multicenter biopsy-based studies with the inclusion of an adequate number of patients are needed to confirm these results.Keywords
All Related Versions
This publication has 22 references indexed in Scilit:
- Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across RadiologistsEuropean Urology Focus, 2019
- Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory studyThe Lancet, 2017
- Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance imagesProceedings of the National Academy of Sciences, 2015
- Artificial neural networks and prostate cancer—tools for diagnosis and managementNature Reviews Urology, 2013
- Combination of C-TRUS with multiparametric MRI: potential for improving detection of prostate cancerWorld Journal of Urology, 2012
- Computerized transrectal ultrasound of the prostate in a multicenter setup (C-TRUS-MS): detection of cancer after multiple negative systematic random and in primary biopsiesWorld Journal of Urology, 2011
- Weiterentwicklung des transrektalen UltraschallsDer Urologe, 2000
- Improving ultrasonographic diagnosis of prostate cancer with neural networksUltrasound in Medicine & Biology, 1999
- Medical imaging by NMRBritish Journal of Radiology, 1977
- The ultrasonic field as a medical tool.1954